By PPN News Staff
The FDA granted a new indication to dapagliflozin (Farxiga, AstraZeneca), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, to reduce the risk for sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease (ESKD), cardiovascular (CV) death and hospitalization for heart failure (HF) in adults with chronic kidney disease (CKD) at risk for progression.
The approval was based on positive results from the DAPA-CKD, an international, multicenter,